Mouse VEGFA peptide

Name: Mouse VEGFA peptide
SKU: DAG341
Rating: 5 (1 reviews)

Recombinant Mouse VEGFA peptide

COA

SDS

Datasheet

Summary

Nature

Recombinant

Tag/Conjugate

Unconjugated

Alternative Names

VPF; VEGF; MVCD1

Format

Purified, Lyophilized Reconstitute using sterile deionized waterto a concentration 100μg/ml. Further dilutions can be made inother aqueou buffers.

Concentration

1 mg/ml(OD280nm, E0.1% = 0.2875) (prior to lyophilization)

Buffer

Notapplicable

Preservative

None

Storage

2-8°C short term, -20°C long term

Entrez Gene ID

7422

Antigen Description

Vascular endothelial growth factor (VEGF) is a signal proteinproduced by cells that stimulates vasculogenesis and angiogenesis. It is partof the system that restores the oxygen supply to tissues when bloodcirculation is inadequate. VEGF"s normal function is to create new bloodvessels during embryonic development, new blood vessels after injury, musclefollowing exercise, and new vessels (collateral circulation) to bypassblocked vessels

Keywords

VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; VEGF-A; MGC70609; vascular permeability factor; vascular endothelial growth factor isoform VEGF165

Citations

Have you cited DAG341 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Genetic Variations of VEGFA Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma

ANTICANCER RESEARCH

Authors: Psoma, Elizabeth; Koliou, Georgia-Angeliki; Dimitrakopoulos, Foteinos-Ioannis; Papadopoulou, Kyriaki; Rontogianni, Dimitra; Bobos, Mattheos; Visvikis, Anastasios; Kosmidis, Paris A.; Fountzilas, George; Constantinidis, Jannis; Kalogera-Fountzila, Anna

Abstract

Background/Aim: The aim of the present study was to investigate the clinical significance of 7 single nucleotide polymorphisms (SNPs) of vascular endothelial growth factor A (VEGFA), endothelin receptor type A (EDNRA), nibrin (NBS1) and Fas cell surface death receptor (FAS) genes in patients with nasopharyngeal carcinoma (NPC). Patients and Methods: Genomic DNA was extracted from the peripheral blood specimens of 60 patients. Genotyping of 4 VEGFA polymorphisms, namely VEGFA -1154 G/A (rs1570360), -2578 A/C (rs699947), -1498 C/T (rs833061) and +936 C/T (rs3025039), as well as EDNRA SNP p.His323 (rs5333), NBS1 p.E185Q (rs1805794) and FAS -671 A/G (rs1800682) was performed by using Sanger sequencing. Results: The VEGFA +936 CC genotype was more frequent in tumors with bilateral infiltration of pterygoid plates compared to those with ipsilateral (76.9% vs. 69.6%, p=0.008) and no infiltration of pterygoid plates (76.9% vs. 68.8%, p=0.023). VEGFA -2578, VEGFA -1154 and VEGFA + 936 were significantly associated with infiltration to the pterygoid processes (p= 0.011, p= 0.041 and p=0.032, respectively). EDNRA H323H TT genotype was marginally associated with infiltration to the ipsilateral medial pterygoid muscles (p=0.045). A trend towards longer overall survival was observed for VEGFA -2578 CC as compared to AC (HR=0.24, p=0.060). Conclusion: The studied VEGFA SNPs seem to be associated with the local extension of the NPC and maybe with the clinical outcome of this patient group.

A New Model Applied for Evaluating a Rhenium-diselenium Drug: Breast Cancer Cells Stimulated by Cytokines Induced from Polynuclear Cells by LPS

ANTICANCER RESEARCH

Authors: Veena, Vijay; Harikrishnan, Adhikesavan; Lakshmi, Basavegowda; Khanna, Sunali; Desmaele, Didier; Collery, Philippe

Abstract

Background/Aim: New anticancer drugs are usually tested on cancer cells in culture in a standard medium. We stimulated immune polynuclear cells by lipopolysaccharides to obtain an enriched medium (EM) containing inflammatory cytokines more closely reflecting the tumor microenvironment and tested a rhenium-diselenium (Re-diSe) drug in this new model. Concentrations of cytokines were compared with a control medium (CM). Materials and Methods: Human-derived breast cancer cells were grown in culture either in CM or EM with or without Re-diSe. Assays of tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL6), intereukin 1 beta (IL1 beta), transforming growth factor-beta (TGF beta), insulin growth factor 1 (IGF1) and vascular epidermal growth factor A (VEGFA) were performed by enzyme-linked immunosorbent assays. The production of reactive oxygen species (ROS) was determined by 2,7-dichlorofluorescein test. The cell growth was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tests. Results: Concentrations of TNF alpha, IL6 and Il1 beta were observed to be significantly higher in EM than in CM. There was no difference for TGF beta, IGF1 and VEGFA. The cells were sensitive to Re-diSe, with reduced concentrations of TGF beta, IGF1, VEGFA and ROS, but the half-maximal inhibitory concentration was significantly higher in EM than in CM. Conclusion: The efficacy of the Re-diSe drug was confirmed in this model of aggressive cancer.